ClinicalTrials.gg
Not yet recruitingNCT03223220QUEST-KETAUpdated Dec 18, 2023

Quelling of Excitotoxicity in Acute Stroke With Ketamine

A Phase 2/3 interventional study of Ketamine and Normal Saline in Acute Ischemic Stroke, sponsored by Lower Merion Neurology Research Foundation. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-12-18.

Sponsored by Lower Merion Neurology Research Foundation · Phase 2/3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 480 studies in Ischemic Stroke with a site in United States — 120 open to participants now, 145 under way, 13 of them phase 3. Ischemic Stroke · United States.

Planned enrollment
133rd of 364
120 · median 65
Started
2024
with 30 others
Phase 2/3
13 of 480
5 open now
Primary completion
2026-12
later than 35 of 144 live
Registered
193rd of 480
by date

Among the 480 studies in Ischemic Stroke with a site in United States, this one is the 133rd largest by planned enrollment of the 364 interventional ones that give a count, is one of 31 that started in 2024, is one of 13 in phase 2/3, reaches primary completion later than 35 of the 144 other live ones, and was the 193rd registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

120 of the 480 studies in Ischemic Stroke with a site in United States are open now. Recruiting first, the newest first:

115 more — sign in →

All 120 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 480 studies in Ischemic Stroke with a site in United States, or all of them as a file.
02

Study summary

The investigators plan to undertake a phase II study to investigate the efficacy and side effects of intravenous ketamine to reduce neuroexcitotoxicity, and thus provide neuroprotection in patients diagnosed with acute ischemic stroke.

Read the detailed description

After obtaining informed consent, patients enrolled in the 'study drug' arm of the trial will receive Ketamine (1 mg/ml solution prepared in normal saline) infusion at a rate of 20 mg/h for a period of 24 hours. The infusion will start at a rate of 5 mg/h, and then gradually tapered up during the first 3 hours by 5 mg an hour. Similarly, the infusion rate will be gradually tapered down at a rate of 5 mg/h during the last 3 hours of infusion. The patients randomized to the 'placebo arm' of the trial will receive normal saline infusion at the same rates. In order to prevent the psychogenic adverse effects associated with Ketamine, the patients will be administered Midazolam at a dose of 1 mg IV every 4 hours. Midazolam will also be administered at the same rate to the patients randomized to the placebo arm. Blood Ketamine levels will be measured before starting the treatment, and daily while the infusion is on. While receiving treatment, the patients will be admitted to the telemetry floor in the hospital, on a monitored bed.

03

Conditions studied

  • Acute Ischemic Stroke

Keywords

  • Stroke, Neuroprotection, Ketamine
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. All patients who are 18 years or older, presenting or admitted to the study site with acute ischemic stroke, up to 24 hours since their last known well time
  2. An MRI evidence of acute ischemic infarct on the diffusion-weighted imaging with ADC correlate
  3. Pre-stroke modified Rankin scale of 0-2
  4. Patient should be willing to participate in the study by providing a written consent himself/herself or through a proxy.

Exclusion criteria

Exclusion Criteria:

  1. Eligibility to receive IV Alteplase or intra-arterial thrombectomy/embolectomy
  2. Longer than 24 hours since last known well time
  3. Pre-stroke modified Rankin scale of 3 or above.
  4. Pregnant or lactating females
  5. Pre-existing psychiatric illness
  6. Intracranial hemorrhage of any type at presentation
  7. Seizure at onset of symptoms
  8. Sustained uncontrolled hypertension defined as Systolic Blood pressure greater than 185 mmHg or Diastolic Blood Pressure greater than 110 mmHg, despite administration of antihypertensive medications
  9. Known or adverse reaction to prior administration of Ketamine
  10. Inability/refusal to provide consent by the patient or through a proxy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Study Drug

    Will receive Ketamine infusion, and Midazolam (Versed).

    Drug: Ketamine · Drug: Midazolam injection

  • Placebo comparator
    Placebo

    Will receive Normal saline infusion and Midazolam (Versed).

    Other: Normal Saline · Drug: Midazolam injection

Interventions

06

What researchers measure

Primary outcomes

  1. Change in weighted modified Rankin scale score between day 1 and 90 will be assessed.

    An improvement of 2 in mRS score will be considered favorable outcome.

    Time frame: On day 1 and at 90 days

Secondary outcomes

  1. Barthel's index

    An improvement of 10 or more points in Barthel's index will be considered a favorable outcome.

    Time frame: On day 1, and at 90 days

  2. NIH stroke scale score

    Time frame: On day 1, day 4 or discharge whichever is earlier, and at 90 days

  3. Depression score using the PHQ9 questionnaire

    Time frame: On day 1, and day 4 or discharge whichever is earlier.

  4. Infarct volumes

    Measured from the DWI-MRI and/or CT images

    Time frame: On day 1, and day 4 or discharge whichever is earlier

  5. All cause mortality

    Time frame: 90 days

  6. Stroke-related mortality

    Time frame: 90 days

  7. Symptomatic intracranial hemorrhage

    Time frame: Day 4 or discharge whichever is earlier

  8. Deterioration in neurologic status

    Increase of 4 or more points in the NIH stroke scale

    Time frame: Up to day 4 or discharge whichever is earlier

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2024; primary completion for Dec 2026, 29 months later.

Of 31 phase 2/3 interventional studies under Ischemic Stroke, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 55. This study's planned 29 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 14, 2017
First posted
Jul 21, 2017
StartEst.
Jul 1, 2024
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2027
Last update
Dec 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03223220
Lead sponsor
Lower Merion Neurology Research Foundation
Responsible party
Sudhir Aggarwal MD, PhD, (Neurologist and Medical Director, Lower Merion Neurology Research Foundation) — Principal investigator
First posted
Jul 21, 2017
Start date
Jul 1, 2024 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Dec 18, 2023

Study contacts

Sudhir Aggarwal, MD, PhD
Contact
saggarwal@lowermerionneurology.com
4844132572

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ketamine

Start the discussion